Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL391642 | 1.00 | MTOR (0.82) | MTORAKT1 | |
| SCHEMBL290800 | 0.90 | MTOR (1.00) | MTORAKT1 | |
| SCHEMBL1217634 | 0.90 | MTOR (1.00) | MTORAKT1 | |
| SCHEMBL4177877 | 0.87 | AKT1 (1.00) | MTORAKT1 | |
| SCHEMBL22449748 | 0.86 | MTOR (0.61) | MTORAKT1 | |
| SCHEMBL393842 | 0.86 | MTOR (0.84) | MTOR | |
| SCHEMBL393843 | 0.86 | MTOR (0.84) | MTOR | |
| SCHEMBL4913107 | 0.84 | AKT1 (0.88) | MTORAKT1 | |
| SCHEMBL2902969 | 0.84 | AKT1 (0.88) | MTORAKT1 | |
| SCHEMBL22449875 | 0.84 | MTOR (0.59) | MTORAKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10034884-B2 | Pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2018-07-31 | — | — | US | disclosed |
| US-10034884-B2 | Pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2018-07-31 | — | — | US | disclosed |
| US-10034884-B2 | Pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2018-07-31 | — | — | US | disclosed |
| US-20170281637-A1 | Pyrido-, Pyrazo- and Pyrimido-Pyrimidine Derivatives as mTOR Inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2017-10-05 | — | — | US | disclosed |
| US-20170281637-A1 | Pyrido-, Pyrazo- and Pyrimido-Pyrimidine Derivatives as mTOR Inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2017-10-05 | — | — | US | disclosed |
| US-20170281637-A1 | Pyrido-, Pyrazo- and Pyrimido-Pyrimidine Derivatives as mTOR Inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2017-10-05 | — | — | US | disclosed |
| US-9717736-B2 | Pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2017-08-01 | — | — | US | disclosed |
| US-9717736-B2 | Pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2017-08-01 | — | — | US | disclosed |
| US-9717736-B2 | Pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2017-08-01 | — | — | US | disclosed |
| EP-2057156-B1 | 2-METHYLMORPHOLINE PYRIDO-,PYRAZO- AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS | KUDOS PHARM LTD (GB) | 2017-02-01 | — | — | EP | disclosed |
| WO-2009050506-A2 | COMBINATION 059 | ASTRAZENECA AB (SE) | 2009-04-23 | — | — | WO | disclosed |
| US-20090099174-A1 | COMBINATION 059 | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | US | disclosed |
| US-20080194546-A1 | Pyrido-, Pyrazo- and Pyrimido-Pyrimidine Derivatives as mTOR Inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2008-08-14 | — | — | US | disclosed |
| US-20080194546-A1 | Pyrido-, Pyrazo- and Pyrimido-Pyrimidine Derivatives as mTOR Inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2008-08-14 | — | — | US | disclosed |
| US-20080194546-A1 | Pyrido-, Pyrazo- and Pyrimido-Pyrimidine Derivatives as mTOR Inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2008-08-14 | — | — | US | disclosed |
| US-20080081809-A1 | Novel Compounds | KUDOS PHARMACEUTICALS LIMITED (GB) | 2008-04-03 | — | — | US | disclosed |
| US-20080081809-A1 | Novel Compounds | KUDOS PHARMACEUTICALS LIMITED (GB) | 2008-04-03 | — | — | US | disclosed |
| US-20080081809-A1 | Novel Compounds | KUDOS PHARMACEUTICALS LIMITED (GB) | 2008-04-03 | — | — | US | disclosed |
| WO-2008023161-A1 | 2-METHYLMORPHOLINE PYRIDO-, PYRAZO- AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS | KUDOS PHARMACEUTICALS LIMITED (GB) | 2008-02-28 | — | — | WO | disclosed |
| WO-2008023161-A1 | 2-METHYLMORPHOLINE PYRIDO-, PYRAZO- AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS | KUDOS PHARMACEUTICALS LIMITED (GB) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099174-A1 | COMBINATION 059 | MTOR, RICTOR, MAPK9 | MTOR 1/4885AKT1 33/4885 |
| US-20170281637-A1 | Pyrido-, Pyrazo- and Pyrimido-Pyrimidine Derivatives as mTOR Inhibitors | MTOR, RICTOR, RPTOR | MTOR 1/4885AKT1 213/4885 |
| US-10034884-B2 | Pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors | MTOR, RICTOR, RPTOR | MTOR 1/4885AKT1 213/4885 |
| US-20080081809-A1 | Novel Compounds | SLC10A1, ABCB11, PKD1 | MTOR 203/4885AKT1 1066/4885 |
| US-20080194546-A1 | Pyrido-, Pyrazo- and Pyrimido-Pyrimidine Derivatives as mTOR Inhibitors | RPS6KB1, RPS6KA1, RPS3A | MTOR 24/4885AKT1 782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.